Renal Cell Carcinoma: Background

作者: Ronald M. Bukowski , Andrew C. Novick

DOI: 10.1007/978-1-60327-149-3_1

关键词: Overall survivalRenal cell carcinomaMale predominanceIncidence (epidemiology)EpidemiologyIn patientEnd resultsInternal medicineCancerMedicineGastroenterology

摘要: Renal cancer accounts for 2 to 3% of all malignant tumors. An estimated 39,000 new cases and 13,000 deaths were predicted 2006.1 is diagnosed in patients ranging from 40 70 years age, with a male predominance 1.6 1.0.1 A comparison 43,685 renal the period 1973 1985 those 1986 1998 (Surveillance, Epidemiology, End Results [SEER] database) demonstrated marginal increase proportion localized cancers decrease advanced latter group. The differences not significant, importantly, overall survival was improved.2 While increased imaging laboratory testing may generally explain incidence, other factors play role.2

参考文章(24)
P Russo, Renal cell carcinoma: presentation, staging, and surgical treatment. Seminars in Oncology. ,vol. 27, pp. 160- 176 ,(2000)
R. M. Bukowski, C. M. Baum, S. T. Kim, R. J. Motzer, T. E. Hutson, R. A. Figlin, M. D. Michaelson, P. Tomczak, S. Oudard, O. Rixe, Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) ASCO Meeting Abstracts. ,vol. 24, ,(2006)
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter, None, The biology of VEGF and its receptors. Nature Medicine. ,vol. 9, pp. 669- 676 ,(2003) , 10.1038/NM0603-669
William Y. Kim, William G. Kaelin, Role of VHL Gene Mutation in Human Cancer Journal of Clinical Oncology. ,vol. 22, pp. 4991- 5004 ,(2004) , 10.1200/JCO.2004.05.061
James C. Yang, Leah Haworth, Richard M. Sherry, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Seth M. Steinberg, Helen X. Chen, Steven A. Rosenberg, A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer The New England Journal of Medicine. ,vol. 349, pp. 427- 434 ,(2003) , 10.1056/NEJMOA021491
Brent K. Hollenbeck, David A. Taub, David C. Miller, Rodney L. Dunn, John T. Wei, National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology. ,vol. 67, pp. 254- 259 ,(2006) , 10.1016/J.UROLOGY.2005.08.050
Herbert T. Cohen, Francis J. McGovern, Renal-cell carcinoma. The New England Journal of Medicine. ,vol. 353, pp. 2477- 2490 ,(2005) , 10.1056/NEJMRA043172
Inderbir S Gill, Minimally invasive nephron-sparing surgery. Urologic Clinics of North America. ,vol. 30, pp. 551- 579 ,(2003) , 10.1016/S0094-0143(03)00030-2
Douglas J. Schwartzentruber, Patrick Hwu, Claudia A. Seipp, Linda Rogers-Freezer, Kathleen E. Morton, Donald E. White, David J. Liewehr, Maria J. Merino, Steven A. Rosenberg, James C. Yang, Richard M. Sherry, Seth M. Steinberg, Suzanne L. Topalian, Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer Journal of Clinical Oncology. ,vol. 21, pp. 3127- 3132 ,(2003) , 10.1200/JCO.2003.02.122
ROBERT C. FLANIGAN, G. MICKISCH, RICHARD SYLVESTER, CATHY TANGEN, H. VAN POPPEL, E. DAVID CRAWFORD, Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis The Journal of Urology. ,vol. 171, pp. 1071- 1076 ,(2005) , 10.1097/01.JU.0000110610.61545.AE